ID
11638
Beschreibung
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis ODM derived from http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Link
http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Stichworte
Versionen (2)
- 24.11.11 24.11.11 -
- 09.07.15 09.07.15 - Martin Dugas
Hochgeladen am
9. Juli 2015
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Psoriasis NCT00216879
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
Beschreibung
Exclusion Criteria
Alias
- UMLS CUI-1
- C0680251
Beschreibung
PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation
Datentyp
boolean
Alias
- UMLS CUI-1
- C0853073
- UMLS CUI-2
- C0018233
Beschreibung
UVB therapy anywhere on the patient within 14 days prior to randomisation
Datentyp
boolean
Alias
- UMLS CUI-1
- C0564461
Beschreibung
Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton
Datentyp
boolean
Alias
- UMLS CUI-1
- C0005522
Beschreibung
Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation
Datentyp
boolean
Alias
- UMLS CUI-1
- C1515119
Beschreibung
Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton
Datentyp
boolean
Alias
- UMLS CUI-1
- C0150349
Beschreibung
Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation
Datentyp
boolean
Alias
- UMLS CUI-1
- C0150349
- UMLS CUI-2
- C0001617
Beschreibung
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
Datentyp
boolean
Alias
- UMLS CUI-1
- C2347852
Beschreibung
Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis
Datentyp
boolean
Alias
- UMLS CUI-1
- C0343052
- UMLS CUI-2
- C0152081
- UMLS CUI-3
- C0748052
Beschreibung
Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
Datentyp
boolean
Alias
- UMLS CUI-1
- C0037278
Beschreibung
Known or suspected severe renal insufficiency or severe hepatic disorders
Datentyp
boolean
Alias
- UMLS CUI-1
- C1565489
- UMLS CUI-2
- C1869009
Beschreibung
Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia
Datentyp
boolean
Alias
- UMLS CUI-1
- C0020437
Beschreibung
Trial subjects should be using an adequate method of contraception
Datentyp
boolean
Alias
- UMLS CUI-1
- C0700589
Ähnliche Modelle
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
C0018233 (UMLS CUI-2)
C0001617 (UMLS CUI-2)
C0152081 (UMLS CUI-2)
C0748052 (UMLS CUI-3)
C1869009 (UMLS CUI-2)